[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-357241-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-357241-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-potential-mutation-defined-polemmrtp53-group-classifications-to-stratify-brca-wild-type-epithelial-ovarian-cancer","A potential mutation-defined POLE/MMR/TP53 group classifications to stratify BRCA wild type epithelial ovarian cancer","","TCGA molecular classification shows prognostic value in endometrial cancer, but its relevance to epithelial ovarian cancer remains unclear. This study analyzed somatic mutations in POLE, MMR genes (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, PMS2), and TP53 in 181 BRCA wild type EOC patients. Mutation patterns differed by histology, FIGO stage, tumor grade, recurrence, and tumor-related death, with distinct differences in disease-free and overall survival. Multivariate analysis identified R0 resection as key for recurrence, while platinum response types predicted tumor-related death. The POLEmut or NSMP groups showed more favorable survival and the panel may serve as a marker.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-potential-mutation-defined-polemmrtp53-group-classifications-to-stratify-brca-wild-type-epithelial-ovarian-cancer/357241/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-potential-mutation-defined-polemmrtp53-group-classifications-to-stratify-brca-wild-type-epithelial-ovarian-cancer/357241.png","ImageObject",300,407,{"name":42,"@type":43},"Jasmine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which mutations were analyzed to define the POLE/MMR/TP53 groups?","Question",{"text":63,"@type":64},"The study investigated somatic mutations in POLE, the MMR genes (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, PMS2), and TP53 in BRCA wild type epithelial ovarian cancer patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did mutation-defined group patterns differ among patient subtypes?",{"text":68,"@type":64},"Mutation patterns varied across histological subtypes, FIGO stage (early vs advanced), tumor grade (low vs high), and clinical outcomes including recurrence and tumor-related death.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors were important predictors in multivariate analyses?",{"text":72,"@type":64},"R0 resection was an important prognostic factor for tumor recurrence, while platinum partial sensitive and platinum resistant responses were key prognostic factors for tumor-related death.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},357241,1790176335,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":124,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336478487870,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Chen et al. Journal of Ovarian Research (2026) 19:219 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-026-02123-9](https://doi.org/10.1186/s13048-026-02123-9)  \nRESEARCH Open Access  \nA potential mutation-defined POLE/MMR/TP53 group classifications to stratify BRCA wild type epithelial ovarian cancer  \nYi-Ting Chen1, Po-Han Lin2,3, Yi-Jou Tai4,5, Heng-Cheng Hsu4,5,6, Kuan-Ting Kuo7 and Ying-Cheng Chiang4,5,8*  \nAbstract  \nBackground TCGA molecular classification has prognostic value in endometrial cancer, but its application in epithelial ovarian cancer is not clear.  \nMethods We investigated the somatic mutations of POLE, MMR (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, PMS2) and TP53, in 181 BRCA wild type EOC patients.  \nResults The patterns were different in histology [ serous vs. endometrioid vs. clear cell (POLEmut: 0% vs. 2. 8% vs. 0%, MMR mut: 6.4% vs. 22. 2% vs. 11. 9%, TP53 mut: 75. 7% vs. 16. 7% vs. 4. 5%, NSMP: 17. 9% vs. 58. 3% vs. 83. 6%, p \u003C 0. 001)]; FIGO stage [early vs. advanced (POLEmut: 1.4% vs. 0%, MMR mut: 11. 3% vs. 11. 8%, TP53 mut: 9 . 8% vs. 55. 5%, NSMP:  \n77. 5% vs. 32. 7%, p \u003C 0. 001)]; tumor grade [low vs. high (POLEmut: 3 . 8% vs. 0%, MMR mut: 19. 2% vs. 10. 3%, TP53 mut:  \n11. 5% vs. 41. 9%, NSMP: 65 . 5% vs. 47. 8%, p = 0. 002)]; tumor recurrence [ no vs. yes (POLEmut: 1.4% vs. 0%, MMR mut:  \n11. 3% vs. 11. 9%, TP53 mut: 21 . 1% vs. 47. 7%, NSMP: 66 . 2% vs. 40.4%, p = 0.002)] and tumor-related death [ no vs. yes (POLEmut: 1. 0% vs. 0%, MMR mut: 9. 2% vs. 14. 5%, TP53 mut: 25 . 5% vs. 51. 8%, NSMP: 64 . 3% vs. 33. 7%, p \u003C 0.001)] . There was difference in median disease-free survival [months (POLEmut: not reached, MMR mut: 12. 5, TP53 mut: 8 . 5, NSMP:  \n36. 5; p = 0 . 002)] and overall survival [months (POLEmut: not reached, MMR mut: 41, TP53 mut: 47, NSMP: not reached; p = 0 . 008)] . In multivariate regression analysis, R0 resection (HR: 0.54 [0 .32–0. 90], p \u003C 0. 001) was important prognostic factor of tumor recurrence. Platinum partial sensitive response (HR: 9.27 [3 .73–23. 01], p \u003C 0. 001) and platinum resistant response (HR: 26.29 [11 .75–58. 82], p \u003C 0. 001) were important prognostic factors of tumor-related death. Conclusions The pattern of mutation-defined POLE/MMR/TP53 group classifications varied in histological subtypes, FIGO stage and clinical outcomes in BRCA wild type EOC. BRCA wild type EOC patients with POLEmut or NSMP had favorable survival than those with MMR mut or TP53mut. The panel could be a potential marker for EOC patients. Keywords Gene mutation group classifications, POLE, MMR, P53, Epithelial ovarian cancer  \n*Correspondence: Ying-Cheng Chiang [ycchiang@ntuh.gov.tw](ycchiang@ntuh.gov.tw)  \n1Department of Obstetrics and Gynecology, National Taiwan University Hospital Yunlin Branch, Douliu City, Yunlin County, Taiwan  \n2Graduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei City, Taiwan 3Department of Medical Genetics, National Taiwan University Hospital, Taipei City, Taiwan  \n4Department of Obstetrics and Gynecology, National Taiwan University Hospital, 15F, No. 8, Chung-Shan South Road, Taipei City, Taiwan 5Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei City, Taiwan  \n6Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei City, Taiwan  \n7Department of Pathology, College of Medicine, National Taiwan University, Taipei City, Taiwan  \n8Department of Obstetrics and Gynecology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu County, Taiwan  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commo","cbCaiuBxBuINBBQD","https://ap.wps.com/l/cbCaiuBxBuINBBQD","pdf",1367630,"English","# Introduction\n## Molecular classification and clinical heterogeneity\n# Abstract\n## Background\n## Methods\n## Results\n## Conclusions","[{\"question\":\"Which mutations were analyzed to define the POLE/MMR/TP53 groups?\",\"answer\":\"The study investigated somatic mutations in POLE, the MMR genes (MLH1, MLH3, MSH2, MSH3, MSH6, PMS1, PMS2), and TP53 in BRCA wild type epithelial ovarian cancer patients.\"},{\"question\":\"How did mutation-defined group patterns differ among patient subtypes?\",\"answer\":\"Mutation patterns varied across histological subtypes, FIGO stage (early vs advanced), tumor grade (low vs high), and clinical outcomes including recurrence and tumor-related death.\"},{\"question\":\"What factors were important predictors in multivariate analyses?\",\"answer\":\"R0 resection was an important prognostic factor for tumor recurrence, while platinum partial sensitive and platinum resistant responses were key prognostic factors for tumor-related death.\"}]","A potential mutation-defined POLE/MMR/TP53 group classifications to stratify BRCA wild type epithelial ovarian cancer | PDF",1790129440,25,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/179bb11400e01183ea1d8c45c6417485.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b24cb295e0b5c39de437cf8ce0caa97.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3421ee7108dc14a96a832a605ba50dc4.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cee75025f3571a083b4fbc39844d91f2.webp",980,1306]